Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs ...

The study also opens the door to new kinds of treatments that do not rely solely on antibiotics. Some of the surviving bacteria are fragile in specific ways, especially in their outer membranes.